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Objective: We sought to compare mitral valve repair and replacement as treatments
for degenerative mitral valve disease with coexisting ischemic heart disease. Specifi-
cally, we sought to (1) identify differences between patients undergoing repair and
replacement, (2) determine whether the choice of mitral valve procedure affected
survival after adjusting for those differences, and (3) discover which patients were
predicted to benefit from mitral valve repair and which from replacement.
Methods: From 1973 to 1999, 679 patients (mean age, 67  9.1 years; 73% men)
with degenerative mitral valve and ischemic heart diseases underwent combined
coronary artery bypass grafting and either mitral valve repair (66%) or replacement
(34%). Factors associated with repair and replacement were used for multivariable
propensity matching. Risk factors for death were identified by means of multivari-
able, multiphase hazard-function analysis.
Results: Patients more likely to undergo repair had isolated posterior chordal rupture
(P  .0001) or more recent date of operation (P  .0001); those more likely to
undergo replacement were older (P  .0003) or had bileaflet prolapse (P  .0001).
Unadjusted survival at 30 days and 1, 5, and 10 years was 97%, 92%, 79%, and 59%
after repair and 94%, 88%, 70%, and 37% after replacement. After adjusting for
comorbid factors, the extent and effect of ischemic heart disease, and propensity
score, the survival benefit of repair became evident after 2 years (P  .01).
Eighty-nine percent of patients were predicted to benefit from repair.
Conclusions: In patients with degenerative mitral valve and ischemic heart diseases,
mitral valve repair confers a survival advantage over replacement that becomes
evident about 2 years after the operation.
With current surgical techniques, most degenerative mitralvalves can be repaired.1-4 Purported advantages of mitralvalve repair over replacement include greater freedom fromreoperation and endocarditis, better preservation of left ven-tricular function, and improved survival.1-9 These advan-tages have been investigated when degenerative mitral valve
disease exists in isolation.1 However, particularly in aging populations with a
limited life expectancy, it often coexists with ischemic heart disease. When a
prolonged combined coronary artery and valve operation is contemplated, the
appropriate valvular surgical strategy (mitral valve repair vs expeditious replace-
ment) is unclear.
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Therefore we have compared long-term survival in pa-
tients with ischemic heart disease undergoing coronary ar-
tery bypass grafting (CABG) with either mitral valve repair
or replacement for degenerative disease. Because selection
of the valve repair or replacement procedure was not ran-
domized, comparison required (1) identifying patient char-
acteristics that were more likely to lead to repair than
replacement at this center, (2) determining whether survival
was better after repair or replacement once those character-
istics were taken into account, and (3) discovering which




Definitions. Classification of degenerative mitral valve disease
was based on standard criteria extracted from review of pathology
reports, echocardiograms, and direct surgical inspection.1,10 If
microscopic pathologic examination revealed myxomatous degen-
eration, the valve was classified as degenerative (although we
recognize that myxoid material might represent a final common
pathway for possible diverse causes). When pathology reports
were unavailable, valves were classified as degenerative if on
echocardiography or inspection they had typical findings of leaflet
prolapse caused by chordal elongation or rupture and thick floppy
leaflets. Finally, those rare patients with annular dilatation and
thick billowing leaflets but without frank leaflet prolapse were
judged to have degenerative mitral valve disease.
Particular care was taken to exclude patients with ischemic
mitral regurgitation. In the setting of ischemic heart disease, mitral
valve regurgitation is caused by ischemic heart disease in about
half of patients and coexists with it in the other half.11 Ischemic
mitral regurgitation is caused by papillary muscle infarction and
elongation, papillary muscle rupture, or failure of leaflet coaptation
caused by leaflet restriction after myocardial infarction.12 Patients
in the latter group, who have functional ischemic mitral regurgi-
tation, are distinguished from patients with degenerative disease by
the presence of leaflet restriction after myocardial infarction and
lack of excess leaflet tissue.
Patient identification. By using these definitions, potential pa-
tients operated on from 1973 to 1999 were identified for this study
by query of the Cardiovascular Information Registry. This registry
contains detailed demographic, clinical, pathologic, operative, and
outcome variables on all patients having cardiac surgery at The
Cleveland Clinic Foundation abstracted from clinical records con-
currently with patient care. Data from this registry has been ap-
proved for use in research by The Cleveland Clinic Foundation’s
Institutional Review Board. Because definitions of valve cause
have evolved and because of the need to clearly separate degen-
erative disease from ischemic disease, search criteria were inten-
tionally broad to cast a wide net that we believed would capture all
instances of degenerative disease and CABG. Medical records of
the 1500 patients so identified were reviewed to verify valve cause,
and this netted 679 patients.
Among these 679 patients, the mitral valve was repaired in 447
and replaced in 232. All had at least 2 (moderate) mitral regur-
gitation. Patients undergoing tricuspid valve repair were included,
but those undergoing aortic valve or Maze procedures were not.
The mean age of patients undergoing mitral valve repair was
67  9.1 years, which was similar to that of patients undergoing
mitral valve replacement (67  9.4 years, P  .4). Patient char-
acteristics overall and according to whether repair or replacement
was performed are given in Tables 1 and 2.
Surgical Details
The decision to perform mitral valve surgery and the choice of
procedure were made by the cardiologist and surgeon. The most
common mitral valve repair technique was annuloplasty, which
was used in 396 patients (89%, Table 3); 70% had leaflet resection.
Among patients undergoing mitral valve replacement, 69% re-
ceived bioprostheses, and 31% received mechanical valves.
All patients had concomitant CABG (Table 4). The mean
number of distal anastomoses was 2.2  1.2 in patients having
mitral valve repair and 2.1  1.1 in patients having mitral valve
replacement (P  .2). An internal thoracic artery (ITA) graft was
used for 62% of patients who underwent repair and 25% of those
who underwent replacement (P  .001).
Aortic clamp time was 88  31 minutes (median, 82 minutes)
in the mitral valve repair group and 84  33 minutes (median, 74
minutes) in the mitral valve replacement group (P  .06).
Tricuspid valve repair was performed in 15 (3%) patients
having mitral valve repair and 10 (4%) having mitral valve re-
placement.
Follow-up
Patients were followed systematically at 2-year intervals with a
mailed questionnaire, a telephone interview, or examination at the
Cleveland Clinic. Mean follow-up among survivors was 5.2  3.6
years, with 25% followed for more than 6 years and 10% for more
than 10 years; 3568 patient-years of information were available for
analysis. Nonparametric survival estimates were considered reli-
able to 11 years.13
Data Analysis
Overview. The primary challenge in comparing long-term sur-
vival after CABG and either mitral valve repair or replacement is
that selection of repair or replacement was not allocated on the
basis of a randomized process. Thus data analysis first addressed
the following question: “Were characteristics of patients undergo-
ing mitral valve repair similar to those of patients undergoing replace-
ment?” Lack of similarity necessitated use of methods specific for
nonrandomized comparisons. We then asked, “Is long-term survival
better after mitral valve repair than after replacement?” A simple
comparison was not possible, and therefore both risk adjustment and
adjustment for nonrandom treatment assignment were used. Finally,
we asked, “Which patients benefit from which procedure?” Multiva-
riable simulation was used to answer this question.
Were characteristics of patients undergoing mitral valve re-
pair similar to those of patients undergoing replacement? Mul-
tivariable logistic regression analysis was used to identify factors
associated with valve repair rather than replacement. In this anal-
ysis demographic characteristics, symptoms and clinical status,
mitral valve pathology, cardiac comorbidity, noncardiac comor-
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bidity, operative details, and experience were considered (Appen-
dix Table 1).
The process of identifying these factors was similar in all
multivariable analyses. Initial screening of variables was per-
formed to ensure that at least 5 events were associated with each
factor considered. Continuous and ordinal variables were exam-
ined by means of decile analysis to discover possible linearizing
transformations of scale that best met model assumptions. Nonin-
formative imputation of sporadic missing values was used.
Selection of risk factors used bootstrap bagging, with auto-
mated analysis of 1000 random data sets by using a P value of .05
or less as the criterion for retention of factors in each model. This






(n  447), No. (%)
Mitral replacement





50 32 (5) 23 (5) 9 (4)
50-60 106 (16) 56 (13) 50 (22)
60-70 252 (37) 179 (40) 73 (31)
70-80 250 (37) 169 (38) 81 (35)
80 39 (6) 20 (4) 19 (8)
Male 496 (73) 336 (75) 160 (69) .08
Cardiac comorbidity
NYHA functional class .002*
I 33 (5) 25 (6) 8 (3)
II 386 (57) 264 (59) 122 (53)
III 213 (31) 136 (31) 77 (33)
IV 45 (7) 20 (4) 25 (11)
Atrial fibrillation 153 (22) 94 (21) 59 (25) .2
Coronary artery disease†
Left main 58 (9) 41 (9) 17 (7) .4
LAD system 502 (74) 326 (73) 176 (76) .4
LCX system 395 (59) 260 (59) 135 (59) .9
RCA system 434 (64) 280 (63) 154 (67) .3
No. of diseased systems .3*
0 25 (5) 20 (6)‡ 5 (3)§
1 205 (30) 139 (31) 66 (29)
2 199 (29) 123 (28) 76 (33)
3 245 (36) 162 (36) 83 (36)
Left ventricular dysfunction .002*
None 376 (56) 263 (59) 113 (49)
Mild 164 (24) 105 (24) 59 (26)
Moderate 94 (14) 59 (13) 35 (15)
Severe 39 (6) 17 (4) 22 (10)
Previous cardiac surgery 44 (6) 29 (6) 15 (6) .9
History of MI 217 (32) 127 (28) 90 (39) .006
Noncardiac comorbidity
Hypertension 307 (56) 226 (55) 81 (58) .6
COPD 67 (10) 49 (11) 18 (8) .2
Diabetes (oral or insulin treated) 73 (12) 43 (10) 30 (14) .15
Renal disease 15 (2) 9 (2) 6 (3) .6
Experience
Year of operation .001
Before 1990 267 (39) 122 (27) 145 (62)
1990-1995 215 (32) 160 (36) 55 (24)
After 1995 197 (29) 165 (37) 32 (14)
LAD, Left anterior descending coronary artery; LCX, lateral circumflex; RCA, right coronary artery; MI, myocardial infarction; COPD, chronic obstructive
pulmonary disease.
*Logistic test for trend.
†Fifty percent or greater diameter stenosis.
‡Six had left main disease only, 1 had an atypical left main lesion, 12 had coronary lesions reported on cineangiography as less than 50% stenosis, and
1 had electrocardiographic changes of ischemia.
§Two had left main disease only, and 3 had coronary lesions reported on cineangiography as less than 50% stenosis.
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was followed by tabulation of the frequency of occurrence at a P
value of .05 or less of both single factors and closely related
clusters of factors.14,15 In the final model only factors occurring in
at least 50% of the analyses were considered statistically signifi-
cant for the parsimonious model.
This parsimonious model was amplified into a propensity
model by adding factors from each class of variables not already
represented (see Appendix Table 1 for these classes).16,17 The
propensity model was solved to generate a propensity score for
each patient, representing the probability of undergoing repair. It
was used in 3 ways in this study: (1) to stratify patients by quintiles
to demonstrate differential survival between repair and replace-
ment17,18; (2) to form propensity-matched pairs by means of
greedy matching for comparison19; and (3) to adjust the multiva-
riable time-related comparison for not only risk factors but also
selection bias.20,21 Results of all 3 types of propensity matching
were similar, and only the results of method 3 are presented.
Is long-term survival better after mitral valve repair than after
replacement? Overall nonparametric estimates of survival were
obtained by using the Kaplan-Meier method.22 A parametric
method was used to resolve the number of phases of instantaneous
risk of death (hazard function) and to estimate its shaping param-
eters.23* Thereafter, multivariable analysis was performed in the
hazard-function domain by using the strategies discussed above.
In all analyses we forced in the variable “mitral valve repair
versus mitral valve replacement” and the propensity score to
obtain an overall estimate of the benefit of repair versus that of
replacement. This was followed by an intense investigation of
factors interacting with type of operation to discover modulating
factors.
Which patients benefit from which procedure? The overall
multivariable survival equation was solved twice for each patient,
once as though the patient’s mitral valve had been replaced and
once as though a repair had been performed (simulation). The
difference between predicted survivals for these 2 strategies at 10
years was compared. A positive difference was interpreted as a
repair benefit and a negative difference as a replacement benefit.
Multiple linear regression of the 10-year survival differences
was performed by using the strategies discussed above. From this,
an algorithm for predicting the strategy for mitral valve repair
versus that for replacement was devised.*For additional details, see http://www.clevelandclinic.org/heartcenter/hazard.
TABLE 3. Mitral valve surgical procedure (n  679)
Procedure No. %
Mitral valve replacement (n  232)
Mechanical 72 31
Bioprosthetic 160 69
Mitral valve repair (n  447)
Annuloplasty 396 89
Annuloplasty type (n  396)
Carpentier-Edwards ring 94 24
Cosgrove ring 206 52
Bovine pericardial 80 20
Autologous pericardium 9 2
Suture 4 1
Other (Gergod, Duran) 2 0.5
Type not stated 1 0.2
Leaflet resection 314 70
Sliding repair 48 11
Chordal transfer 60 13
Chordal shortening 51 11
TABLE 2. Mitral valve pathology
Pathophysiology
Total (n  679),
No. (%)
Mitral repair
(n  447), No. (%)
Mitral replacement
(n  232), No. (%) P value
Mitral regurgitation grade
2 56 (8) 37 (8) 19 (8) .4
3 232 (34) 147 (33) 85 (37)
4 388 (57) 262 (59) 126 (54)
Not stated 3 1 2
Prolapsed leaflet
Any 661 (97) 439 (98) 222 (96) .05
Posterior only 340 (50) 280 (63) 60 (26) .001
Anterior only 132 (20) 83 (19) 49 (21) .4
Bileaflet 157 (23) 68 (15) 89 (39) .001
Location not stated 32 8 24
None* 18 (3) 8 (2) 10 (4)
Ruptured chordae
Any 422 (63) 308 (69) 114 (50) .001
Posterior only 314 (47) 259 (58) 55 (24) .001
Anterior only 63 (9) 32 (7) 31 (14) .007
Bileaflet 31 (5) 10 (2) 21 (9) .001
Location not stated 14 7 7
Elongated chordae 206 (31) 121 (27) 85 (37) .008
*Isolated dilatation (see text for definitions).
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Mortality and survival estimates are accompanied by an asymmet-
ric 68% confidence interval, which is comparable to 1 SE.
Throughout, model coefficients are given with their SEs rather
than either odds ratios (logistic) or hazard ratios (time-related
analyses). This is because hazard ratios lose simple meaning in the
setting of transformations of scale of continuous variables to
obtain appropriate calibration and a time-related events model that
is one of nonproportional hazards.
Both logistic regression and hazard-function models were
solved for specific sets of values for variables to illustrate the
results in a risk-adjusted fashion.
Results
Were Characteristics of Patients Undergoing Mitral
Valve Repair Similar to Those of Patients Undergoing
Replacement?
The answer to the question of whether characteristics of
patients undergoing mitral valve repair are similar to those
of patients undergoing replacement is no (Tables 1 and 2).
Factors associated multivariably with a greater likelihood of
repair included isolated posterior chordal rupture, more
recent date of operation, and younger age. Factors associ-
ated multivariably with replacement were bileaflet prolapse
and previous cardiac surgery (Table 5). There was a striking
increase in the prevalence of mitral valve repair in more
recent experience (Figure 1, A). Increasing prevalence of
repair in recent years corresponds to the era during which
ITA grafting became increasingly routine (Figure 1, B); this
explains the higher ITA use among patients undergoing
repair (Table 4). Figure 2 shows the relationship of age and
probability of repair in patients with and without isolated
posterior chordal rupture.
Is Survival Better After Mitral Valve Repair Than
After Replacement?
The answer to the question of whether survival is better
after mitral valve repair than after replacement is not simple.
It depends on patient characteristics.
Non–risk-adjusted survival comparison: early mortal-
ity. Thirty (4.4%; confidence limit [CL], 3.6%-5.4%) pa-
tients died in the hospital: 16 (3.6%; CL, 2.7%-4.7%) after
mitral valve repair and 14 (6.0%; CL, 4.4%-8.1%) after
mitral valve replacement (P  .14). Thirty-day mortality
was 3.1% after mitral valve repair and 5.6% after replace-
ment (P  .12), and operative mortality (hospital mortality
and patients dying within 30 days) was 4.0% and 6.5% (P
.16), respectively.
Non–risk-adjusted survival comparison: time-related
survival. For the entire group, unadjusted survival was 76%
at 5 years and 46% at 10 years. For the repair group,






(n  447), No. (%)
Mitral Replacement
(n  232), No. (%) P value
ITA grafting 333 (49) 276 (62) 57 (25) .001
LITA used 236 (35) 201 (45) 35 (15) .001
Complete revascularization 495 (73) 344 (77) 151 (66) .001
No. of grafts .15
1 245 (36) 162 (36) 83 (36)
2 181 (27) 106 (24) 75 (32)
3 175 (26) 121 (27) 54 (23)
4 78 (11) 58 (13) 20 (9)
LITA, Left ITA.




coefficient  SE P value
Demography
Younger age* 0.59 0.16 .0003
Valve pathology
Isolated posterior chordal rupture 1.22 0.22 .0001
Bileaflet prolapse† 1.24 0.24 .0001
Retracted leaflet† 1.28 0.50 .01
Noncardiac comorbidity
Peripheral vascular disease† 0.61 0.26 .02
Experience
Previous cardiac surgery† 1.02 0.38 .008
Date of operation‡
Recent 0.49 0.07 .0001




†Negative sign indicates increased chances of mitral valve replacement.
‡Complex relation shown in Figure 1.
§(opyears/15)3 Cubic transformation.
Twenty-four patients had regional posterior leaflet prolapse and, at a
different portion of the posterior leaflet, an abnormal chordal mesh, caus-
ing leaflet retraction.
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survival was 79% and 59% at 5 and 10 years, and for the
replacement group, it was 70% and 37%, respectively (Figure
3, A). The unadjusted survival curves diverged at about 4 years
because of earlier divergence (less than 2 years) of the late
rising phase of the hazard (Figure 3, B), with patients under-
going mitral valve replacement having a marked increase in
mortality risk compared with those undergoing repair.
Propensity and risk-adjusted comparison. The nonpro-
portional hazards model resulted in 3 phases of instantaneous
risk of death in the overall study group. After using the pro-
pensity score to adjust for dissimilarities inpatient characteris-
tics between those undergoing mitralvalve repair versus re-
placement and othervariables for risk adjustment, replacement
was identified as a risk factor for death in the late hazard phase,
beginning about 2 years after the operation (Table 6). During
the early hazard phase (operation to 6 months), survival was
similar after repairand replacement; in the constant hazard
phase (6 months to 3.5 years) there was possibly improved
survivalin patients undergoing repair, but this varied with age.
Which Patients Benefit From Which Procedure?
Simulation with the multivariable equation (Table 6) indi-
cated that 89% of patients would have better 10-year sur-
vival after repair compared with after replacement of the
Figure 1. Trends in prevalences of procedures by calendar year. Each symbol represents the actual proportion of
patients in each calendar year who underwent the procedure indicated. Solid lines with 68% CLs are estimated
trend lines. A, Prevalence of mitral valve repair versus replacement; B, prevalence of use of ITA grafting in patients
undergoing repair or replacement.
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mitral valve (Figure 4). Linear regression produced a clin-
ical algorithm useful for suggesting whether repair or re-
placement should be used in a patient (Appendix 2). For
example, Figure 5, A, shows predicted time-related survival
in a 70-year-old patient coming to operation in New York
Heart Association (NYHA) class II, with no other cardiac or
noncardiac risk factors. Such a profile is typical of patients
referred in the current era. Predicted survival after mitral
valve repair and replacement diverges at about 4 years, with
better survival after repair. In contrast, Figure 5, B, shows
predicted survival in a 70-year-old diabetic patient in
NYHA class IV with severe left ventricular dysfunction
from previous myocardial infarcts. Survival is limited after
a mitral valve operation and concomitant CABG, with no
advantage of either strategy for managing the mitral valve.
Discussion
Key Findings
In our institution the choice of valve procedure in patients
with degenerative mitral valve and ischemic heart diseases
depended on patient characteristics, valve pathophysiology,
and surgical era. After accounting for these differences, the
survival benefit of mitral valve repair became evident after
about 2 years. Eighty-nine percent of patients with degen-
erative mitral valve and ischemic heart diseases were pre-
dicted to benefit from repair versus replacement, and these
patients can be identified with an algorithm that predicts the
effect of mitral valve procedure in individual patients.
Implications of Differences Among Patients
Undergoing Mitral Valve Repair Versus Replacement
Patients who underwent mitral valve repair differed in im-
portant respects from many patients who underwent re-
placement. As a group, elderly patients have more advanced
degenerative disease with more prolapse than do younger
patients with isolated mitral valve degeneration.1 In the
analysis of mitral valve repair versus replacement, we ap-
proached the potential confounding of outcome from these
differences by using propensity score adjustment.16-18
In our institution patients with complex mitral valve
pathology, such as bileaflet prolapse, were more likely to
have their valves replaced. Other investigators have noted a
similar experience.5,6,8,9 Although repair of anterior or
bileaflet prolapse is challenging, multiple surgical tech-
niques can provide reliable and durable results.1-4 With
current surgical techniques, most patients with anterior leaf-
let prolapse can be offered durable valve repair.1,10
Mitral Valve Repair Versus Replacement
In elderly patients with ischemic heart disease, surgeons
might be tempted to replace rather than repair the mitral
valve, presuming that the choice of procedure will have
little or no effect on survival. In addition, valve replacement
is easily and reliably completed, generally requiring less
time than repair.
We documented several risk factors for early and late
death after surgical treatment of degenerative mitral valve
and ischemic heart diseases. These included general factors,
such as older age, advanced NYHA functional class, severe
Figure 2. Relationship between age and probability of mitral valve repair in patients with and without isolated
posterior chordal rupture.
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left ventricular dysfunction, preoperative atrial fibrillation,
and renal dysfunction. Mitral valve replacement emerged as
a risk factor for late death after adjustment for these factors
and the propensity score.
It is generally accepted that mitral valve repair rather
than replacement confers a survival advantage. Although
Akins and colleagues7 and Enriquez-Sarano and associates9
found that repair was associated with reduced hospital mor-
tality, we and others5,24 did not. Sand and coworkers5 found
that mitral valve replacement might be a risk factor for late
death. In a study limited to patients with degenerative dis-
ease, Lee and colleagues6 concluded that surgical procedure
(mitral valve repair, replacement with subvalvular preser-
vation, or replacement without subvalvular preservation)
did not affect 6-year survival.
The previously mentioned studies suffer from small
numbers of patients5,6 and populations that include multiple
causes for mitral valve dysfunction.5,7-9 It is particularly
Figure 3. Time-related survival after CABG and either mitral valve repair or replacement. A, Each symbol represents
a death according to the Kaplan-Meier estimator. Vertical bars enclose asymmetric 68% CLs. Solid lines represent
parametric survival estimates; these are enclosed between dashed 68% CLs. Numbers in parentheses are numbers
of patients traced beyond that point. B, Hazard functions (instantaneous risk) for death after CABG and mitral valve
repair or replacement.
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important to distinguish patients with ischemic mitral re-
gurgitation from those with concomitant degenerative mitral
valve and ischemic heart diseases. Patients with ischemic
mitral regurgitation have a poor prognosis.12
Which Patients Benefit From Repair?
Eighty-nine percent of patients with degenerative mitral
valve and ischemic heart diseases were projected to derive
a survival benefit from mitral valve repair versus replace-
ment. Even in elderly patients with ischemic heart disease,
repair is desirable. However, patients in NYHA class IV
with extreme left ventricular dysfunction have poor sur-
vival, regardless of mitral valve procedure, and present a
contemporary surgical challenge.
Limitations
This was a nonrandomized clinical study. By using the
propensity score, we attempted to adjust the multivariable
analyses of outcomes for nonrandom selection bias related
to the choice of valvular procedure.
The end point of this study was death.25 We did not
analyze other valve-related complications, all of which have
been thoroughly documented in the literature on mitral
valve repair and replacement. For similar reasons, we did
not examine valve durability or reoperation.1,10,26
We were unable to determine from review of the oper-
ative reports which patients with mitral valve replacement
had preservation of all or part of the subvalvular apparatus.
Thus we could not analyze the effect of this surgical tech-
nique directly. However, because the procedure became
Figure 4. Cumulative distribution of differences in 10-year survival between mitral valve repair and replacement.
Patients to the right of 0 difference are predicted to benefit from repair and those to the left from replacement.
TABLE 6. Incremental risk factors for death




Mitral valve replacement 0.005 0.45 .9
Propensity adjustment* 0.59 0.70 .4
Older age† 1.03 0.25 .0001
Elongated chordae 1.00 0.37 .007
Bilirubin 0.43 0.17 .01
LITA graft 1.12 0.57 .05
Constant hazard phase
Mitral valve replacement‡ 3.8 2.5 .13
Propensity adjustment 0.29 1.01 .8
Older age† 0.49 0.26 .06
Younger age in patients undergoing
replacement§
1.43 0.65 .03
Higher NYHA functional class 0.69 0.25 .006
Moderate or severe LV dysfunction 1.03 0.33 .002
Preoperative atrial fibrillation 0.76 0.33 .02
Preoperative BUN level 0.048 0.011 .0001
Late hazard phase
Mitral valve replacement 1.24 0.51 .01
Propensity adjustment 0.71 0.48 .13
Older age† 0.89 0.19 .0001
Diabetes 0.88 0.30 .003
Smoking history 0.88 0.24 .0002
LITA, Left internal thoracic artery; LV, left ventricular; BUN, blood urea
nitrogen.
*Probability of receiving mitral valve repair.
†exp(age/50) Exponential transformation.
‡Represents increment to intercept for patients undergoing mitral valve
repair.
§Interaction term.
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standard practice at the Clinic in 1988, we analyzed the
interaction between the date of operation and valve replace-
ment as a surrogate and did not identify a statistically
significant relationship.
Clinical Inferences and Decision Making
Choice of surgical procedure affects late survival in patients
with degenerative mitral valve disease coexisting with isch-
emic heart disease. Most patients benefit from mitral valve
repair.
We thank Karen Mrazeck for assembling and verifying the
clinical data and performing the follow-up, Linda DiPaola and
Angela Eshelman for constructing the data set, and Tess Knerik for
editorial assistance. Dr Norman Ratliff importantly contributed to
clarifying the criteria for differentiating between ischemic and
degenerative mitral valve cause.
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Appendix 1
Variables considered in risk analyses
Demographic characteristics
Age (years)
Body size: height (centimeters), weight (kilograms), body mass
index, body surface area (square meters)
Sex
Symptoms and clinical status
NYHA class, emergency surgery
Mitral valve pathology
Prolapse of the anterior leaflet, prolapse of the posterior leaflet,
elongated chordae to the anterior leaflet, elongated chordae to the
posterior leaflet, rupture of the anterior chordae, rupture of the
posterior chordae, dilated annulus, leaflet retraction
Cardiac comorbidity
Previous cardiac surgery, family history of coronary artery
disease, preoperative atrial fibrillation, left ventricular dysfunction
(graded as none, mild, moderate, or severe), history of myocardial
infarction, coronary artery disease (maximum stenosis in left main
trunk, left anterior descending, circumflex, and right coronary
trunk systems), number of coronary systems with greater than 50%
stenosis (0-3)
Noncardiac comorbidity
Blood urea nitrogen, creatinine, renal disease, cholesterol, bil-
irubin, treated diabetes, smoking, hypertension, chronic obstruc-
tive pulmonary disease, peripheral vascular disease
Operative details
Mitral valve replacement versus repair
Mitral prosthesis: bioprosthesis, mechanical
Mitral repair: site of repair (annulus, posterior leaflet, anterior
leaflet); use of annuloplasty (type of ring: Carpentier-Edwards,
Cosgrove, Edwards; bovine pericardial annuloplasty); leaflet re-
section (partial or complete, sliding or not); chordal resection;
chordal shortening or transfer
CABG: ITA grafting, single versus bilateral ITA grafting;
number of grafts; complete revascularization
Experience
Date of operation expressed on a continuous scale as years
from January 1, 1973.
Appendix 2. Algorithm to choose mitral valve strategy
Analysis of 10-year survival difference for mitral valve
repair versus replacement yields an algorithm that aids in
deciding which strategy to pursue. Estimating the 10-year
survival difference is a 4-step process. First, select one
value for each of the 3 continuous variables from the
columns below. Enter these values into the table on the
following page.
Age Value BUN Value Bilirubin Value
35 2.2 10 16.6 0.3 0.43
40 2.9 12 16.1 0.4 0.57
45 3.7 14 15.2 0.5 0.71
50 4.5 16 14.2 0.6 0.85
55 5.5 18 13.0 0.7 0.99
60 6.5 20 11.9 0.8 1.14
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Dr Tirone E. David (Toronto, Ontario, Canada). I would like
to congratulate Dr Faber and his colleagues from the Cleveland
Clinic for having attempted to demonstrate the relative values of
mitral valve repair and mitral valve replacement in patients with
mitral regurgitation caused by myxomatous degeneration and as-
sociated coronary artery disease. I have to confess that I do not
understand the statistical methods he used to adjust for the differ-
ences in the patients’ clinical profile, but I trust Eugene Blackstone
so much that I have to accept their conclusions.
What is evident to me, however, is that your patients who had
mitral valve replacement were operated on much earlier in your
experience than those who had mitral valve repair. Actually, 62%
of your patients who had mitral valve replacement were operated
on before 1990, and 73 of those who had mitral valve repair were
operated on after 1990. This alone suggests to me a change in
approach at your institution, that the surgeons who are facing the
problem decided to change the way they manage their problem. In
addition, patients who had mitral valve replacement were much
older, they are much more symptomatic, and they had worse
ventricular function than patients who had mitral valve repair.
There was no mention in your presentation or your manuscript
that I reviewed, thanks to you, as to whether the papillary muscles
and chordae tendineae were preserved during mitral valve replace-
ment. Years ago we published an article showing that mitral valve
repair or replacement with the preservation of the chordae tendi-
neae had similar 10-year survival if the patients had isolated mitral
valve regurgitation caused by myxomatous disease.
I have a couple of questions for you, Dr Faber. Were the
papillary muscles preserved in any of your patients, and if they
were, was the result the same?
The second question is related to the ITA. We have shown over
and over that revascularization of the internal descending artery
with the left ITA enhances life span. Forty-five percent of your
mitral valve repairs used the ITA, whereas this was the case in only
15% of the replacements. Could this difference alone account for
most of the difference found in survival?
Finally, there must be a number of patients in whom, even after
1990, when your surgeons were more experienced in mitral valve
repair, your surgeons attempted to repair the mitral valve, and then,
after a while, 30 minutes or an hour, they abandoned the procedure
and replaced the valve. Those patients, if they were lumped to-
gether with the elective mitral valve replacements, had a much
worse prognosis than those who had mitral valve replacement to
start with.
Dr Faber. Dr David, thank you very much for your kind
comments, and those are very important issues that you pointed
out. I would like to say that we did not have the information about
the preservation of the subvalvular apparatus on the operative
reports of the patients, so we could not say which ones we
preserved and which ones we did not preserve. I know about the
results of your article, and I agree with them, but we could not
analyze that data, and that probably could be accounting for some
of the differences that we saw.
Dr David. I am sorry to dwell on this issue. Did you take a look
at temporal response of mitral valve replacement as well? In other
words, of the patients who were operated on after 1990 and had
mitral valve replacement, did those patients do better than those
operated on in 1973?
Dr Faber. I do not know the answer for this. We did not look
into that. The only thing we know is that after we gained more
experience with repair, we started doing more and more of those,
but we did not look specifically at the time frame of those.
Therefore I could not answer this question for you.
About the ITA differences in survival, yes, I agree with that,
and it has been shown that there is a difference in survival. Still,
this, in the beginning of our experience, was based on the decision
of the surgeon. Therefore I could not say why they used that. But
I agree with your comments, and lately, that is what we use for the
revascularization of the LAD.
What was your last question?















BUN, Blood urea nitrogen; LV, left ventricular.
*Grade 3 (moderately severe) or 4 (severe) left ventricular dysfunction.
†Only those of the posterior leaflet.
§Pharmacologically treated (real hypoglycemic agents or insulin).
Third, sum all the numbers in the column marked “Value chosen.”
Fourth, interpret the total. The total is the estimated 10-year survival
difference in percentage. If the sum is positive, repair is favored; if
negative, replacement is recommended. Approximate error of the survival
difference is 5.5%.
Example: The patient is 70 years old (8.9) in sinus rhythm (0 for atrial
fibrillation) without ventricular ectopy (0) but with only posterior
chordal rupture and leaflet prolapse (1.2) in NYHA class III (9.6)
with 3-system coronary artery disease and well-preserved left ventric-
ular function (0) who has never smoked (0), has no history of diabetes
(0), has a blood urea nitrogen value of 18 (13.0), and has a bilirubin
value of 0.8 (1.14). The total score is 9.96  5.5, meaning mitral valve
repair is recommended.
Appendix 2. Continued
Age Value BUN Value Bilirubin Value
65 7.7 22 10.7 0.9 1.28
70 8.9 24 9.6 1.0 1.42
75 10.2 26 8.5 1.1 1.56
80 11.6 28 7.5 1.2 1.71
85 13.1 30 6.5 1.4 1.99
35 4.1 1.8 2.55
40 1.9 2.2 3.12
BUN, Blood urea nitrogen.
Gillinov et al Surgery for Acquired Cardiovascular Disease
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 6 1361
A
CD
